EPAS1 and nonpapillary renal cell carcinoma: ccRCC is uniquely suited for this exploitation since the majority (more than 80%) of ccRCC harbor VHL mutation, which conveys distinct characteristics on tumor cells and drives tumor development via HIF (either HIF-1α or HIF-2α) stabilization27, 29, 30.